Na tego rocznym kongresie the European Association of Urology (EAU) w Barcelonie zostało przedstawione dosyć sensacyjne doniesienie naukowe:
EAU 2019: Testosterone Slows Recurrence in Patients With Low-Risk Prostate Cancer
Published in Advanced Prostate Cancer March 21, 2019
Thomas Ahlering, MD, of the University of California, Irvine, noted that this finding was surprising because it was not the initial topic of investigation. Testosterone replacement did not increase recurrence, and in fact, it lowered recurrence rates.
According to Dr. Ahlering, the testosterone is not curing the cancer, but is slowing its growth, resulting in an average of 1.5 additional years before cancer can be detected. This is an additional benefit of testosterone, which is known to improve muscle mass, cholesterol and triglyceride levels, and sexual activity.
Dr. Ahlering noted that this is the largest study to suggest that testosterone may not be dangerous for select patients. Although changes to treatment methods are not currently suggested, the taboo against the use of testosterone in low-risk patients following radical prostatectomy should be questioned.
The oncology/urology community should consider reviewing the use of testosterone.
Testosterone has long been regarded testosterone as promoting prostate cancer. The dramatic impact of testosterone reduction on prostate cancer was first reported in 1941. Since then, anti-testosterone therapy has become a standard option for a vast number of patients.
In the late 1990s to 2000s, it was discovered that though men on long term anti-testosterone treatments were not dying from prostate cancer, they were dying prematurely of cardiovascular disease.
It seemed that, though anti-testosterone therapies were treating prostate cancer, extremely low testosterone levels were worsening metabolic complications such as elevated blood sugar, diabetes, elevated cholesterol, and mid-abdomen visceral fat significantly.
Low testosterone also caused a loss of sexual function in many men receiving anti-androgen treatment. This led to the suggestion of testosterone treatment in some low-risk men after radiation or surgery.
In 2008, Dr. Ahlering and colleagues began to carefully select patients for testosterone replacement after robotic radical prostatectomy in hopes of improving their recovery of sexual function.
The team worked with 834 patients undergoing radical prostatectomy. They treated 152 low-risk patients with no evidence of disease with testosterone replacement therapy.
After a median of 3.1 years following surgery, they tested patients for biochemical recurrence, as indicated by measurement of the Prostate Specific Antigen (PSA) levels.
Zawsze podawaj link do źródła. Thnx.
-zb
https://www.practiceupdate.com/content/ ... ncer/81090